<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; outcomes</title>
	<atom:link href="http://www.tapanray.in/tag/outcomes/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Deliver The Best Patient Outcomes With Right High-Tech-High-Touch Combo</title>
		<link>http://www.tapanray.in/deliver-the-best-patient-outcomes-with-right-high-tech-high-touch-combo/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=deliver-the-best-patient-outcomes-with-right-high-tech-high-touch-combo</link>
		<comments>http://www.tapanray.in/deliver-the-best-patient-outcomes-with-right-high-tech-high-touch-combo/#comments</comments>
		<pubDate>Mon, 13 Dec 2021 00:00:55 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[care]]></category>
		<category><![CDATA[Covid]]></category>
		<category><![CDATA[COVID-19]]></category>
		<category><![CDATA[delivery]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[high-tech]]></category>
		<category><![CDATA[high-touch]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[marketers]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[new normal]]></category>
		<category><![CDATA[outcomes]]></category>
		<category><![CDATA[pandemic]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[Physician]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Telehealth]]></category>
		<category><![CDATA[telemedicine]]></category>
		<category><![CDATA[value]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10621</guid>
		<description><![CDATA[Healthcare is regarded as an industry where high-quality technology and high-quality human touch can’t possibly be separated from each other, ever. Since long, this is considered essential in delivering better treatment outcomes – the core value most patients desire, and &#8230; <a href="http://www.tapanray.in/deliver-the-best-patient-outcomes-with-right-high-tech-high-touch-combo/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/deliver-the-best-patient-outcomes-with-right-high-tech-high-touch-combo/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>What Have And Haven’t Changed In Pharma’s New Normal?</title>
		<link>http://www.tapanray.in/what-have-and-havent-changed-in-pharmas-new-normal/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=what-have-and-havent-changed-in-pharmas-new-normal</link>
		<comments>http://www.tapanray.in/what-have-and-havent-changed-in-pharmas-new-normal/#comments</comments>
		<pubDate>Sun, 26 Sep 2021 00:00:39 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[Aduhelm]]></category>
		<category><![CDATA[analytics]]></category>
		<category><![CDATA[augmenting]]></category>
		<category><![CDATA[brand]]></category>
		<category><![CDATA[centric]]></category>
		<category><![CDATA[changed]]></category>
		<category><![CDATA[Costs]]></category>
		<category><![CDATA[COVID-19]]></category>
		<category><![CDATA[creation]]></category>
		<category><![CDATA[customers]]></category>
		<category><![CDATA[data]]></category>
		<category><![CDATA[delivery]]></category>
		<category><![CDATA[disease]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[hits]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[marketers]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[misses]]></category>
		<category><![CDATA[modeling]]></category>
		<category><![CDATA[New]]></category>
		<category><![CDATA[normal]]></category>
		<category><![CDATA[Not]]></category>
		<category><![CDATA[Old]]></category>
		<category><![CDATA[outcomes]]></category>
		<category><![CDATA[Oxymoron]]></category>
		<category><![CDATA[pandemic]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[relationship]]></category>
		<category><![CDATA[repurposed]]></category>
		<category><![CDATA[sensitivity]]></category>
		<category><![CDATA[strategy]]></category>
		<category><![CDATA[support]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Telehealth]]></category>
		<category><![CDATA[transformation]]></category>
		<category><![CDATA[treatment]]></category>
		<category><![CDATA[trends]]></category>
		<category><![CDATA[triggered]]></category>
		<category><![CDATA[vaccines]]></category>
		<category><![CDATA[value]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10588</guid>
		<description><![CDATA[While navigating through the challenge of disruptive changes, several pharma marketers are now focusing more on creating, connecting, and leveraging all market and customer related data, across the organization. Astute ones are using state-of-the-art tools, platforms, and techniques to gain &#8230; <a href="http://www.tapanray.in/what-have-and-havent-changed-in-pharmas-new-normal/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/what-have-and-havent-changed-in-pharmas-new-normal/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Honing Patient Outcomes With WHDs</title>
		<link>http://www.tapanray.in/hoing-patient-outcomes-with-whds/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=hoing-patient-outcomes-with-whds</link>
		<comments>http://www.tapanray.in/hoing-patient-outcomes-with-whds/#comments</comments>
		<pubDate>Mon, 02 Dec 2019 00:00:39 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[care]]></category>
		<category><![CDATA[Democratization]]></category>
		<category><![CDATA[Devices]]></category>
		<category><![CDATA[digital]]></category>
		<category><![CDATA[Fitbit]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[honing]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Internet]]></category>
		<category><![CDATA[opportunities]]></category>
		<category><![CDATA[outcomes]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[penetration]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[smartphone]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[wearable]]></category>
		<category><![CDATA[Wearables]]></category>
		<category><![CDATA[WHD]]></category>
		<category><![CDATA[World]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9791</guid>
		<description><![CDATA[On November 01, 2019, San Francisco-based Fitbit, Inc. announced that it has entered into a definitive agreement to be acquired by Google LLC for approximately US$ 2.1 billion. Many believe, though, the value of Fitbit lies in the health data that its &#8230; <a href="http://www.tapanray.in/hoing-patient-outcomes-with-whds/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/hoing-patient-outcomes-with-whds/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Gamification in Pharma: Creates Engaging Patient Experience For Better Results</title>
		<link>http://www.tapanray.in/gamification-in-pharma-creates-engaging-patient-experience-for-better-results/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=gamification-in-pharma-creates-engaging-patient-experience-for-better-results</link>
		<comments>http://www.tapanray.in/gamification-in-pharma-creates-engaging-patient-experience-for-better-results/#comments</comments>
		<pubDate>Mon, 21 Jan 2019 00:00:23 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Autism]]></category>
		<category><![CDATA[awareness]]></category>
		<category><![CDATA[better]]></category>
		<category><![CDATA[chronic]]></category>
		<category><![CDATA[digital]]></category>
		<category><![CDATA[disease]]></category>
		<category><![CDATA[doctor]]></category>
		<category><![CDATA[engagement]]></category>
		<category><![CDATA[engaging]]></category>
		<category><![CDATA[EVO]]></category>
		<category><![CDATA[experience]]></category>
		<category><![CDATA[gamification]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[management]]></category>
		<category><![CDATA[medicine]]></category>
		<category><![CDATA[motivate]]></category>
		<category><![CDATA[mySugr]]></category>
		<category><![CDATA[outcomes]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[Project]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[relationship]]></category>
		<category><![CDATA[Roche]]></category>
		<category><![CDATA[Self]]></category>
		<category><![CDATA[strategy]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[treatment]]></category>
		<category><![CDATA[unique]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9373</guid>
		<description><![CDATA[On January 03, 2019, media reports flashed &#8211; “A video game-based ‘digital medicine’ tool can help reduce symptoms in children with autism spectrum disorder (ASD) and attention/deficit-hyperactivity disorder (ADHD).” This study was published in the Journal of Autism and Developmental Disorders, confirming &#8230; <a href="http://www.tapanray.in/gamification-in-pharma-creates-engaging-patient-experience-for-better-results/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/gamification-in-pharma-creates-engaging-patient-experience-for-better-results/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Pharma To Facilitate Self-Managing Chronic Diseases For Better Outcomes?</title>
		<link>http://www.tapanray.in/pharma-to-facilitate-self-managing-chronic-diseases-for-better-outcomes/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=pharma-to-facilitate-self-managing-chronic-diseases-for-better-outcomes</link>
		<comments>http://www.tapanray.in/pharma-to-facilitate-self-managing-chronic-diseases-for-better-outcomes/#comments</comments>
		<pubDate>Mon, 07 Jan 2019 00:00:48 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[ailments]]></category>
		<category><![CDATA[Apple]]></category>
		<category><![CDATA[apps]]></category>
		<category><![CDATA[behavioral]]></category>
		<category><![CDATA[Change]]></category>
		<category><![CDATA[chronic. diseases]]></category>
		<category><![CDATA[companies]]></category>
		<category><![CDATA[facilitate]]></category>
		<category><![CDATA[Google]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[incidence]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[mHealth]]></category>
		<category><![CDATA[NCD]]></category>
		<category><![CDATA[NCDs]]></category>
		<category><![CDATA[need]]></category>
		<category><![CDATA[outcomes]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[self-managing]]></category>
		<category><![CDATA[startups]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[tech]]></category>
		<category><![CDATA[treatment]]></category>
		<category><![CDATA[unmet]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9342</guid>
		<description><![CDATA[“India&#8217;s burden of non-communicable disease (NCD) is escalating, but still the country does not have sufficiently detailed data on NCDs for research and policy purposes.” This was captured in a recent study, titled “India&#8217;s escalating burden of non-communicable diseases,” published in The Lancet Global Health on &#8230; <a href="http://www.tapanray.in/pharma-to-facilitate-self-managing-chronic-diseases-for-better-outcomes/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/pharma-to-facilitate-self-managing-chronic-diseases-for-better-outcomes/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Should Pharma-Doctor Communication Be Also Gender-Specific?</title>
		<link>http://www.tapanray.in/should-pharma-doctor-communication-be-also-gender-specific/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=should-pharma-doctor-communication-be-also-gender-specific</link>
		<comments>http://www.tapanray.in/should-pharma-doctor-communication-be-also-gender-specific/#comments</comments>
		<pubDate>Mon, 26 Nov 2018 00:00:13 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[better]]></category>
		<category><![CDATA[care]]></category>
		<category><![CDATA[choosing]]></category>
		<category><![CDATA[communication]]></category>
		<category><![CDATA[concordance]]></category>
		<category><![CDATA[content]]></category>
		<category><![CDATA[doctors]]></category>
		<category><![CDATA[female]]></category>
		<category><![CDATA[Gender]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[internists]]></category>
		<category><![CDATA[male]]></category>
		<category><![CDATA[Medical]]></category>
		<category><![CDATA[mortality]]></category>
		<category><![CDATA[outcomes]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[physicians]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[specific]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9268</guid>
		<description><![CDATA[Regardless of situations, while selecting a suitable doctor for patients, or for that matter, pharma companies engage with them for commercial reasons, their gender doesn’t matter much to many. What one generally looks for is, whether they are General Practitioners &#8230; <a href="http://www.tapanray.in/should-pharma-doctor-communication-be-also-gender-specific/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/should-pharma-doctor-communication-be-also-gender-specific/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>‘One Indian, One Health Record’:  Is EHR A Tentative Intent?</title>
		<link>http://www.tapanray.in/one-indian-one-health-record-is-ehr-a-tentative-intent/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=one-indian-one-health-record-is-ehr-a-tentative-intent</link>
		<comments>http://www.tapanray.in/one-indian-one-health-record-is-ehr-a-tentative-intent/#comments</comments>
		<pubDate>Mon, 05 Nov 2018 00:00:15 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Aadhar]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[Barriers]]></category>
		<category><![CDATA[cost quality]]></category>
		<category><![CDATA[digital]]></category>
		<category><![CDATA[EHR]]></category>
		<category><![CDATA[electronic]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[intent]]></category>
		<category><![CDATA[medicine]]></category>
		<category><![CDATA[notification]]></category>
		<category><![CDATA[one health record]]></category>
		<category><![CDATA[One Indian]]></category>
		<category><![CDATA[outcomes]]></category>
		<category><![CDATA[Policy]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[record]]></category>
		<category><![CDATA[Singapore]]></category>
		<category><![CDATA[speed]]></category>
		<category><![CDATA[standards]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[tentative]]></category>
		<category><![CDATA[treatment]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9247</guid>
		<description><![CDATA[The ongoing march of technology, at a scorching pace, transforming our everyday personal &#8211; working and social lives. This is palpable. In tandem, it is also making traditional processes of doing successful business less and less productive, over a period &#8230; <a href="http://www.tapanray.in/one-indian-one-health-record-is-ehr-a-tentative-intent/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/one-indian-one-health-record-is-ehr-a-tentative-intent/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Pharma Policy Execution Gap Limits Access To Affordable Medicines?</title>
		<link>http://www.tapanray.in/pharma-policy-execution-gap-limits-access-to-affordable-medicines/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=pharma-policy-execution-gap-limits-access-to-affordable-medicines</link>
		<comments>http://www.tapanray.in/pharma-policy-execution-gap-limits-access-to-affordable-medicines/#comments</comments>
		<pubDate>Mon, 15 Oct 2018 00:00:21 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2001]]></category>
		<category><![CDATA[2012]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[affordable]]></category>
		<category><![CDATA[Association]]></category>
		<category><![CDATA[Ayushman Bharat]]></category>
		<category><![CDATA[Based]]></category>
		<category><![CDATA[big]]></category>
		<category><![CDATA[declaration]]></category>
		<category><![CDATA[Doha]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[execution]]></category>
		<category><![CDATA[gap]]></category>
		<category><![CDATA[HTA]]></category>
		<category><![CDATA[implementation]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[National]]></category>
		<category><![CDATA[negotiation]]></category>
		<category><![CDATA[NPPP]]></category>
		<category><![CDATA[outcomes]]></category>
		<category><![CDATA[patented]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[payers]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Policy]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[scheme]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Trade]]></category>
		<category><![CDATA[treatment]]></category>
		<category><![CDATA[value]]></category>
		<category><![CDATA[VBP]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9215</guid>
		<description><![CDATA[“The cost of new drugs is putting increasing pressure on people in both rich and poor countries”- was eloquently expressed in an article, titled “Why do new medicines cost so much, and what can we do about it?”. This was &#8230; <a href="http://www.tapanray.in/pharma-policy-execution-gap-limits-access-to-affordable-medicines/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/pharma-policy-execution-gap-limits-access-to-affordable-medicines/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>‘Design Thinking’: Translating Struggles into Positive Outcomes in Pharma</title>
		<link>http://www.tapanray.in/design-thinking-translating-struggles-into-positive-outcomes-in-pharma/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=design-thinking-translating-struggles-into-positive-outcomes-in-pharma</link>
		<comments>http://www.tapanray.in/design-thinking-translating-struggles-into-positive-outcomes-in-pharma/#comments</comments>
		<pubDate>Mon, 24 Sep 2018 00:00:38 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[company]]></category>
		<category><![CDATA[culture]]></category>
		<category><![CDATA[design]]></category>
		<category><![CDATA[Design thinking]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[organization]]></category>
		<category><![CDATA[outcomes]]></category>
		<category><![CDATA[problem]]></category>
		<category><![CDATA[prototype]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[solution]]></category>
		<category><![CDATA[solving]]></category>
		<category><![CDATA[struggles]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[thinking]]></category>
		<category><![CDATA[UCB]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9196</guid>
		<description><![CDATA[Problems of various nature will keep coming on business, as long as long as one remains in the business. It doesn’t spare anyone in the organization – from the very top to right up to the very bottom. All is &#8230; <a href="http://www.tapanray.in/design-thinking-translating-struggles-into-positive-outcomes-in-pharma/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/design-thinking-translating-struggles-into-positive-outcomes-in-pharma/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Making Drug Pricing Transparent May Work Better Than Price Control</title>
		<link>http://www.tapanray.in/making-drug-pricing-transparent-may-work-better-than-price-control/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=making-drug-pricing-transparent-may-work-better-than-price-control</link>
		<comments>http://www.tapanray.in/making-drug-pricing-transparent-may-work-better-than-price-control/#comments</comments>
		<pubDate>Mon, 23 Jul 2018 00:00:37 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Amgen]]></category>
		<category><![CDATA[Based]]></category>
		<category><![CDATA[control]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[Eli Lilly]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Levitra (vardenafil)]]></category>
		<category><![CDATA[Michelin]]></category>
		<category><![CDATA[Monsanto]]></category>
		<category><![CDATA[Novartis]]></category>
		<category><![CDATA[OBP]]></category>
		<category><![CDATA[outcomes]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[transparent]]></category>
		<category><![CDATA[value based pricing]]></category>
		<category><![CDATA[VBP]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9060</guid>
		<description><![CDATA[“Now, one-fourth of the Indian pharma market to be under price control.” This possibility was reported by some national dailies, on July 03, 2018. The new methodology of drug price control could be anything – ranging from earlier ‘cost-based’ model to the &#8230; <a href="http://www.tapanray.in/making-drug-pricing-transparent-may-work-better-than-price-control/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/making-drug-pricing-transparent-may-work-better-than-price-control/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
